 |
Vaxil's areas of interest, which offer the highest potential for its product development efforts, are:
> Cancer: Development of ImMucin™, a multi-epitope cancer vaccine to the MUC1 tumor associated antigen (TAA). ImMucin has received regulatory approval to enter a first in man Phase I/II clinical trial in Multiple Myeloma patients scheduled to start in 2010.
> Tuberculosis: Development of mTbuVax™, an improved multi-antigenic and multi-epitope vaccine against the intracellular pathogenic bactria mycobacterium Tuberculosis (Mtb). mTbuVax™ is aimed to replace the current GCG vaccines and/or boost the immunity in BCG immunized patients.
Vaxil was founded in early 2007 by an experienced management team supported by leading scientists and clinicians. It is headquartered at the Weizmann Science Park, Nes –Ziona.
|
| Vaxil BioTherapeutics Ltd. is a private company developing a new class of synthetic T cell therapeutic and preventive vaccines with promiscuous MHC class I and II binding, based on its proprietary VaxHit™ technology. |
|